Format

Send to

Choose Destination
Prostate. 2004 Sep 1;60(4):332-7.

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

Author information

1
UCHSC, 4200 E. 9th Ave. C-319, Denver, CO, USA. al.barqawi@uchsc.edu

Abstract

PURPOSE:

To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC).

MATERIALS AND METHODS:

Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented. HER-2 receptor overexpression was evaluated using immunohistochemistry (IHC) and dual-color fluorescence in-situ hybridization (FISH) assays.

RESULTS:

Trastuzumab as a single agent demonstrated little efficacy in treating HRPC. Two patients demonstrated stable disease based on a decrease in PSA level to less than 50% of baseline. No patient demonstrated a regression of radiographic bony or soft tissue metastatic disease. The medication was well tolerated in 16 patients (89%), and 2 patients (11%) had to be hospitalized for cardiac complications.

CONCLUSIONS:

Trastuzumab (Herceptin) as a single agent demonstrated poor efficacy in treating HRPC. Based on promising results in treating breast cancer with regimens using Herceptin and cytotoxic agents, a similar combination approach might demonstrate better efficacy in treating HRPC.

PMID:
15264245
DOI:
10.1002/pros.20065
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center